Figures & data
Table 1. Gating strategies for ILC cells and their subsets (ILC-1, ILC-2, ILC-3, ILC-3 NCR+, ILC-3 NCR.
Table 2. Characteristic of atopic dermatitis patients.
Table 3. The count of total lymphocytes, ILC cells and their subsets (ILC-1, ILC-2, ILC-3, ILC-3 NCR+, ILC-3 NCR-) in AD patients and control group, statistical analysis.
Table 4a. AD severity and the count of ILC cells in AD patients without dupilumab therapy. The relation between AD severity and the count of ILCs and their subsets was not confirmed (≥ 0.05).
Table 4b. AD severity and the count of ILC cells in all AD patients (with and without dupilumab therapy). the relation between AD severity and the count of ILCs and their subsets was not confirmed (≥ 0.05).
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.